Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins

The capsid of human immunodeficiency virus type 1 (HIV-1) is a shell that encloses viral RNA and is highly conserved among many strains of the virus. It forms a conical structure by assembling oligomers of capsid (CA) proteins. CA dysfunction is expected to be an important target of suppression of H...

Full description

Saved in:
Bibliographic Details
Published inBiomolecules (Basel, Switzerland) Vol. 11; no. 2; p. 208
Main Authors Kobayakawa, Takuya, Yokoyama, Masaru, Tsuji, Kohei, Fujino, Masayuki, Kurakami, Masaki, Boku, Sayaka, Nakayama, Miyuki, Kaneko, Moemi, Ohashi, Nami, Kotani, Osamu, Murakami, Tsutomu, Sato, Hironori, Tamamura, Hirokazu
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 03.02.2021
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The capsid of human immunodeficiency virus type 1 (HIV-1) is a shell that encloses viral RNA and is highly conserved among many strains of the virus. It forms a conical structure by assembling oligomers of capsid (CA) proteins. CA dysfunction is expected to be an important target of suppression of HIV-1 replication, and it is important to understand a new mechanism that could lead to the CA dysfunction. A drug targeting CA however, has not been developed to date. Hydrophobic interactions between two CA molecules via Trp184/Met185 in CA were recently reported to be important for stabilization of the multimeric structure of CA. In the present study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site, was synthesized and its significant anti-HIV-1 activity was confirmed. Structure activity relationship (SAR) studies of its derivatives were performed and provided results that are expected to be useful in the future design and development of novel anti-HIV agents targeting CA.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Current address: Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.
ISSN:2218-273X
2218-273X
DOI:10.3390/biom11020208